Ischemic heart disease Board decisions

The Board granted service connection for a right pelvis disability but denied service connection for heart, skin, ankle, and chronic fatigue syndrome disabilities.

The Board remands the claims for service connection for various conditions, including anxiety, PTSD, depression, high blood pressure, a stomach condition, both eyes disability, heart condition, and headaches, due to pre-decisional duty to assist errors and to perform additional development regarding participation in TERA.

The Board remands the claims for service connection for ischemic heart disease and diabetes mellitus type II to obtain additional evidence, including VA treatment records and medical opinions.

The claims for service connection are remanded due to the need for further development of evidence regarding exposure to herbicides at Fort Chaffee, Arkansas.

The Board granted service connection for coronary artery disease with cardiomyopathy and congestive heart failure, finding that the Veteran's current heart diagnoses are related to his in-service pericarditis episode.

The Board remands the claims for service connection due to a need for additional development, including verification of toxic exposure risk activities and obtaining medical opinions.

The Board granted a 100 percent rating for PTSD and a 30 percent rating, and no higher, for ischemic heart disease with myocardial infarction residuals.

The Board remands the claims for service connection for hypertension, ischemic heart disease, and peripheral neuropathy of both hands and feet to obtain additional evidence regarding in-service exposure to herbicide agents.

The Board denied service connection for coronary artery disease, an eye condition, a skin condition, diabetes mellitus type 2, and erectile dysfunction as the evidence did not support a link to the Veteran's active military service.

The Board granted an effective date of March 22, 2019, for the awards of service connection for arteriosclerotic heart disease (CAD), prostate cancer, and hypertension.

The Board granted service connection for hypertensive heart disease as secondary to the Veteran's already service-connected hypertension.

The Board granted an effective date of January 15, 2023, for the award of service connection for coronary artery disease (CAD) and a 100 percent rating from that date. The claims for earlier effective dates for right and left upper extremity peripheral neuropathy were denied.

The Board granted service connection for the Veteran's cause of death, which was determined to be substantially or materially contributed to by diabetes mellitus, type II and hypertension, both caused by obesity resulting from a service-connected disability.

The Veteran's coronary artery disease was granted a 100 percent disability rating and special monthly compensation at the housebound rate, effective October 18, 2021. The issue of entitlement to a total disability rating based on individual unemployability (TDIU) is dismissed as moot.

The Board granted service connection for esophageal cancer with metastases and coronary artery disease, but denied service connection for a respiratory/lung disorder.

The Board granted service connection for coronary artery disease, prostate cancer, and bladder cancer due to presumed exposure to herbicide agents during the Veteran's service in the Korean DMZ.

The Board denied the Veteran's petitions to readjudicate previously denied claims for service connection due to a lack of new and relevant evidence.

The Board granted service connection for ischemic heart disease, diagnosed as coronary artery disease including CABG and MI, based on the Veteran's presumed exposure to herbicide agents during his service near the Korean demilitarized zone.

The Board granted the request to readjudicate the claim for service connection for a heart condition due to new and relevant evidence submitted by the Veteran.

The Board remands the claim for an adequate medical opinion to determine the etiology of the Veteran's causes of death, including pneumonia, COPD, heart disease, and myocardial infarction.